Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A tweak or an outrage? Germany passes new pricing law

This article was originally published in Scrip

Executive Summary

Germany has officially passed its contentious new drug pricing law, which imposes an extended price freeze, scraps retrospective AMNOG assessments, reduces mandatory discounts from 16% to 7% and most controversially of all clarifies that parts of the German system will use confidential rebated prices as the "official" price as opposed to list prices. To some, this last, relatively small aspect of the law is a violation of the constitution, while others say the debate surrounding this tweak to the law has been blown out of proportion.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts